Palivizumab-resistant respiratory syncytial virus was isolated from an infant treated with palivizumab. A stable mutation at codon 276 led to a nearly complete resistance to palivizumab. Additional studies revealed a second mutation at codon 272. Further passage of the virus led to a complete loss of binding of palivizumab.
mmHg. He received respiratory support (nasal positive-airway pressure maximum, 4 mbar; FiO 2 , 0.5) for 6 days. RSV RNA was found at 464,000,000 K/mL (C t value, 17.2). This virus was isolated and further characterized.
Methods. Detection of RSV RNA was performed by a 1step multiplex real-time polymerase chain reaction (PCR), as described elsewhere [3] . Semiconfluent monolayers of HEp-2 cells were maintained in Dulbecco's Modified Eagle Medium with 2% fetal bovine serum and were infected with the cellfree supernatant of the pharyngeal aspirate. Extracellular virions were harvested and stored at Ϫ80ЊC [4] . Three passages were obtained (P1, P2, and P3). Further passages were cultured in a similar manner with and without the addition of palivizumab at a concentration of 8.9 ng/mL to the medium; viral growth was determined by limiting dilution (tissue culture infectious dose; TCID 50 ). The microneutralization assay was performed as described elsewhere, with modifications [5] . One hundred TCID 50 of virus were incubated with serially diluted palivizumab before being added to the HEp-2 cells. Three days later, cells were fixed with acetone-methanol and enzyme-linked immunosorbent assay was performed with MAb mouse anti-RSV F protein (Serotec MCA490) and MAb anti-RSV N protein (Serotec MCA491) as detector antibodies and anti-mouse IgG HRPO (Amersham NA9310V) as the second antibody. Mean absorbance at 490 nm was recorded. Immunofluorescence was performed in acetone-methanol-fixed cells. Palivizumab, a human hRSV-positive serum, Mab47F, and Mab2F** [6] (provided by J. Melero) were used as first antibodies. Sequence data were determined directly from reverse transcription PCR products, which were derived from amplification with 2 RSV F genespecific primers encompassing nearly the complete F gene. Nucleotide alignment with group A and B sequences was performed by the neighbor-joining method with use of the MEGA software package, version 4.
Results. Virus inoculation of the patient's pharyngeal aspirate in HEp-2 cells led to a moderate cytopathic effect on the 3rd day after infection. The microneutralization assay with palivizumab showed a decrease in virus growth up to a concentration of 142 mg/mL ( Figure 1B ). This in contrast to the results for laboratory strain RSV-Long, which showed an palivizumab ID 50 of 9.0 ng/mL (95% confidence interval, 3.7-22.0 ng/mL). Several passages were performed with and without the addition of palivizumab (8.9 mg/mL). The microneutralization assay of the second passage with the addition of palivizumab demonstrated a complete resistance to palivizumab ( (ID 50 , 199.4 ng/mL; 95% confidence interval, 81-490 ng/mL), compared with the second passage of RSV-Long without the addition of palivizumab ( Figure 1D , RSV-VI-1447Pal[Ϫ]P2). There was an increase in the growing titers of the virus passages, starting with TCID 50 /mL for the first passage to 3 1 ϫ 10 TCID 50 /mL for the second passage. Immunofluores- 4 1 ϫ 10 cence was performed on different passages, P1 without palivizumab, P2 without palivizumab, and P2 with palivizumab. In contrast to human polyclonal serum, there was significant decrease in the binding of palivizumab and MAb47F and MAb2F for the first passage, compared with RSV-Long. There is a complete loss of reactivity for palivizumab and MAb47F but not for MAb2F with cells of the second and higher passages in the presence of palivizumab (RSV-VI-1447Pal[+]P2). In contrast, cells of the second passage without palivizumab (RSV-VI-1447Pal[Ϫ]P2) demonstrated a slightly stronger reactivity with these antibodies, as did the cells of the first passage (data not shown). Sequence alignment of the RSV F gene of RSV-VI-1447 with 150 hRSV sequences (National Center for Biotechnology GenBank) revealed RSV-VI-1447 clustering to hRSV group A. Sequence analysis of the F gene PCR amplicon of the patient sample and of further passages demonstrated a stable nucleotide exchange at position 827 from A to G, which leads to an amino acid change from asparagine to serine (N276S) ( Table 1 ) that was not influenced by palivizumab supplementation to the culture conditions. An alignment with 36 hRSV-A sequences from GenBank and 16 hRSV-A sequences from our own laboratory revealed that this mutation is only found in RSV-VI-1447. Alignment with 16 hRSV-B sequences from GenBank showed that serine is regularly found at position 276. Sequence analysis of the cell culture supernatant with higher concentrations of palivizumab in the neutralization assay, as well as of the supernatant of the second passage of the virus in the presence of palivizumab (RSV-VI-1447Pal[+]P2), revealed a second mutation at nucleotide position 814 from A to G, which leads to an amino acid change at position 272 from lysine to glutamic acid (K272E). This mutation was not found in passages of the virus without the addition of palivizumab to the culture medium. Discussion. In vulnerable infants, consequences of RSV infection are critical, with an increased likelihood of intensive care admission and mechanical ventilation. Passive immunization with palivizumab reduces the risk in vulnerable infants of acquiring RSV. The finding of palivizumab-resistant RSV infection might be of clinical relevance [7] .
The described patient was at high risk for RSV-related illness. Therefore, passive immunization was performed according to international guidelines. However, despite 3 injections with palivizumab, our patient developed RSV infection and required hospitalization. Diagnostic examination revealed a palivizumab-resistant RSV strain as the underlying cause.
hRSV escape mutants resistant to palivizumab have been described only in animal studies, especially with cotton rats [2, 8, 9] , and in vitro studies [1] . These studies revealed a region encompassing amino acids 262-276 of the F protein as the Downloaded from https://academic.oup.com/cid/article-abstract/51/2/185/302613 by guest on 02 April 2020 Table 1 putative drug-binding region, where mutations can potentially confer resistance to palivizumab.
. Sequence Changes in the Respiratory Syncytial Virus (RSV) Fusion Protein Found in the Amplicons of the Initial Sample from the Patient (RSV-VI-1447samp) and the Supernatant of the Following Passages in HEp-2 Cells, Compared with the RSV-Long Strain
RSV-VI-1447 has 2 mutations within the drug-binding region, which caused the resistance to palivizumab. We found, both in the original specimen of the patient and in all cell culture passages of the isolated virus, an amino acid exchange from asparagine to serine (N276S). Although this mutation had thus far not been found in RSV-A but is regularly found in RSV-B, it is noteworthy that all the other group-specific positions in this part of the F protein are RSV-A specific (ie, positions 247 [V in RSV-A vs L in RSV-B], 305 [L vs I], 326 [T vs I], and 356 [E vs D], underlining the fact that RSV-VI-1447 clusters to group A. Therefore, we can speculate that the N276S mutation appears only in the context of the RSV-A protein, with a partial resistance against palivizumab, which provokes further mutations leading to a complete resistance. Mutations at position 276 of the F protein have been found with the murine RSV-neutralizing MAb 1237 and lead to an amino acid exchange from asparagine to tyrosine (N276Y) [10] , indicating that this position is sensitive to selection pressure. RSV-VI-1447 shows a ∼20-fold increase in resistance to palivizumab, compared with the Long strain. Binding of palivizumab is impaired, as demonstrated by immunofluorescence analysis. It is not clear whether N276S in a RSV-A strain is a natural but rare mutant or it emerged under the selection pressure of palivizumab.
The second mutation is an amino acid change from asparagine to guanine (K272E). There are several in vivo animal studies and in vitro experiments showing that position 272 is a critical drug-binding site for palivizumab, leading to a change from lysine to methionine, asparagine, threonine, or glutamine [1, 11] . Recombinant approaches generating a panel of mutants at this position demonstrated significantly reduced binding of palivizumab [12] . The mutation found in this study (K272E) has once been described in an in vivo study involving infants receiving palivizumab [13] , but this virus did not grow in cell culture. The authors concluded that this virus had a decreased fitness or that the antibody was still partially effective. We clearly show that RSV-VI-1447 with this K272E mutation has a complete loss of binding of palivizumab and a second MAb [6] binding in the same region. We could not detect this K272E mutation by sequencing the amplicon obtained from the original specimen and from the first passage of cell culture. The occurrence of the mutation in a further passage with the selection pressure of palivizumab and in the supernatant of the initial microneutralization assay of the first passage, which is functionally the same, indicates that the K272E mutation must be present as a minor population together with a partially palivizumab-sensitive wild-type virus at this stage. This is reflected by the neutralization assay ( Figure 1B) , which still shows a slightly inhibiting effect of palivizumab with higher concentrations, and by immunofluorescence, which demonstrates a reduced but still present binding of palivizumab (data not shown).
Hospitalization due to RSV infection in subjects who received palivizumab is rare but well described. Breakthrough infection is more likely during the first and second injection interval or when palivizumab administration was performed in a clinic or office [14, 15] . Our findings might explain this observation, because subjects could become infected when trough levels of palivizumab are low but generate selection pressure to render the resistant virus, leading to infection or transmission.
That RSV-VI-1447 lost its resistance to palivizumab as soon as the selection pressure was no longer present has impact for the clinical and epidemiologic role of such mutants. The occurrence of specific resistance mutations seems to be an individual phenomenon during prophylaxis with palivizumab with implications for the distribution of resistant mutants in the population. This also includes the possibility that under certain circumstances, such as in a clinic or office, nosocomial infections of palivizumab-resistant hRSV strains could occur. Therefore, surveillance studies on the development of resistant viruses in infants receiving palivizumab should be initiated to increase our understanding of their clinical impact.
